Skip to content

The Effect of Malaria on Disease Progression of HIV/AIDS

The Effect of Malaria on Disease Progression of HIV/AIDS in Kumasi, Ghana

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00499876
Enrollment
197
Registered
2007-07-12
Start date
2007-10-31
Completion date
2009-12-31
Last updated
2017-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Infections, Malaria

Keywords

Human immune deficiency virus, Acquired immune deficiency syndrome, malaria, mefloquine, prophylaxis, HIV/AIDS, Treatment Naive

Brief summary

The purpose of this study is to find out whether malaria affects how HIV/AIDS disease progresses in an infected patient, and to determine the effect of reducing malaria infection on HIV disease progression in Kumasi

Detailed description

Malaria and HIV are among the most prevalent infectious diseases in sub-Saharan Africa and are major causes of morbidity and mortality in the sub region. Because of the wide-spread geographical overlap in HIV and malaria, the probability for co-infections and the potential for interactions between the two diseases are high. Even modest interactions may have substantial impact in populations. It is now clear that there are interactions between the two infections. HIV associated immunosuppression erodes the malaria acquired immunity of the HIV patients. The risk of parasitaemia, high parasite density and malarial fever increases with decreasing CD4 T cell counts and increasing viral load of HIV patients. Plasmodium falciparum has been shown to stimulate HIV replication through the production of cytokines (including interleukin 6 and tumor necrosing factor α (TNF-α)) by activated lymphocytes. Malaria treatment in HIV patients with malaria resulted in significant reduction of the median HIV viral load concentration. Although it is now clear that malaria causes transient rises in HIV-1 viral loads, could repeated episodes of malaria in areas of intense transmission lead to a cumulative effect on viral load and accelerate decline in CD4 counts thereby accelerating HIV disease progression? If so, could the decline in CD4 count in individuals who have not yet started on anti-retroviral drugs be slowed down by intermittent malaria treatment? A controlled interventional study with mefloquine as malaria prophylaxis for 6 months will be used in HIV/AIDS patients who are not already on ARTs in KATH, and malaria parasitaemia and density, HIV viral load and CD4 cell count will be monitored in both arms. Comparison: Malaria parasitaemia and density, HIV viral loads and CD4 cell counts will be compared between the intervention group and the control groups to determine the effect o malaria and malaria prophylaxis on HIV disease progression

Interventions

DRUGmefloquine

250mg weekly PO for 6 months

OTHERplacebo

1 tablet weekly PO for 6 months

Sponsors

Noguchi Memorial Institute for Medical Research
CollaboratorOTHER
London School of Hygiene and Tropical Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult HIV patients attending the Komfo Anokye Teaching Hospital (KATH) HIV clinic who do not yet fulfil the criteria for ARTs. This includes a CD 4 cell count of ≥ 300x106/l and World Health Organisation HIV stage I-III

Exclusion criteria

* All children with HIV infection attending the HIV clinic at KATH * Adult HIV patients on ARTs attending the HIV clinic at KATH * Adult HIV patients with WHO stage IV and V AIDS

Design outcomes

Primary

MeasureTime frame
Measure the effects of antimalarials on CD4 cell count decline and HIV viral load increase in study patients12 months

Secondary

MeasureTime frame
Measure the effect of malaria prophylaxis on malaria parasitaemia and haemoglobin levels in study patients12 months

Countries

Ghana

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026